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Abstract
Summary In a randomized, cross-over study, once monthly
administration of vitamin D3 was preferred over a once daily
administration of a fixed-dose combination of vitamin D3 and
calcium, with a better compliance but without any significant
difference in the increase in vitamin D levels.
Introduction The aim of the present study was to compare a
once-monthly administration of vitamin D3 to a daily admin-
istration of a fixed-dose combination of vitamin D3 and cal-
cium during two treatment periods of 6 months.
Methods One hundred volunteers aged 50 years old or older
were randomized to receive either one drinkable ampoule con-
taining 25,000 IU vitamin D3 (D-Cure®, SMB) once monthly
(group VD) or one chewable tablet containing 1000 mg cal-
cium carbonate+800 IU vitamin D3 (Steovit Forte®, Takeda)
once daily (group VDCa) during 6 months. After the first
6 months of treatment, the groups were reversed according
to the randomized cross-over design. Treatment compliance
(i.e. the primary outcome), preference, acceptability and vita-
min D levels and adverse events were all collected.
Results For the two periods, the patients had a significantly
higher compliance in the VD group than in the VDCa group
(p<0.0001). During the study, 50 (56.8 %) patients preferred
the VD treatment, 16 (18.2 %) patients preferred the VDCa,
and for 22 (25.0 %) patients, neither treatment was preferred.
At the end of the first 6 months of treatment, the mean (SD)
increase of 25(OH)D was 6.57 ng/mL (8.19) in the VD group
and 3.88 ng/mL (10.0) in the VDCa group (p=0.16 between
groups).
Conclusion In this study, a once-monthly administration of
vitamin D3 was preferred over a once-daily administration
of a fixed-dose combination of vitamin D3 and calcium, with
a better compliance but without any significant difference in
the increase in vitamin D levels.
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Introduction
Treatment compliance, defined as the extent to which a patient
acts in accordance with the prescribed interval and dose as
well as dosing regimen, is a key factor in the management of
bone health, in the same way as in other chronic diseases [1].
Patient compliance improves effectiveness of osteoporosis
treatment. When patients comply, there is a rise of bone min-
eral density, reduction of fracture risk, and improved quality of
life [1, 2]. Unfortunately, long-term compliance with treat-
ment has been shown to be poor in osteoporosis and about
half of patients stop therapy within 1 to 2 years [3]. Compli-
ance could even be lower with supplementation with calcium
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and/or vitamin D [4]. For example, it has been suggested, in a
multicentre study conducted in Spain, that only two in ten
patients effectively comply with calcium and vitamin D treat-
ment after 1 year or more of its prescription [5].
However, calcium and vitamin D are essential for the main-
tenance of bone homeostasis. Most of the current guidelines
recommend a daily intake of calcium in postmenopausal
women of at least 1000 to 1200 mg, together with at least
800 IU of vitamin D [6, 7]. Besides its effect on falls and
fractures, results from ecological, case-control and cohort
studies have also shown that high vitamin D levels were
associated with reduced risks of autoimmune diseases,
type 2 diabetes, cardiovascular diseases and cancers
[8]. Unfortunately, vitamin D status of the general pop-
ulation is largely below the recommended level. Indeed,
it is estimated that one billion people worldwide have
vitamin D deficiency or insufficiency [9].
Regarding calcium, the needs for adults are generally rec-
ognized as the intake required to maintain calcium balance
and therefore skeletal integrity [10]. The Recommended Die-
tary Allowance (RDA) for European adults is 800 mg/day.
After menopause, the calcium requirements increase to at least
1000 mg/day [11]. Most of the epidemiological studies sug-
gest that calcium intake in this population is below the recom-
mendations [12, 13].
Recent data suggest that there is an increased risk of inci-
dent myocardial infarction in patients taking calcium [14–16].
However, other studies or critical reviews of the literature by
other groups of researchers do not support this finding
[17–22]. As a consequence, the safety of calcium supplements
has drawn much controversy, especially since its use is be-
coming more prevalent [23]. Obviously, this could also have
an impact on compliance with calcium supplementation.
Another factor impacting compliance with treatment is the
frequency of treatment administration [1]. In the field of bone
health, pharmacological interventions, including vitamin D
supplementation, have been developed with daily, weekly,
monthly or multiannually regimes with the objective to im-
prove compliance. This is particularly sensible with vitamin D
because such an approach offers a realistic and pragmatic
public health measure to target at-risk populations and ad-
dresses the emerging public health issue of widespread vita-
min D insufficiency. However, still with vitamin D, dosing
intervals of more than 2–3 months and/or intermittent bolus
doses (200,000 IU) are not regarded as physiological and
could affect clinical outcomes because of a difference in the
bioavailability of vitamin D [24, 25]. The question of the ideal
time between doses is, however, still of debate.
The aims of the present study are to compare the compli-
ance with a once-monthly administration of vitamin D3 to
compliance with a daily administration of a fixed-dose com-
bination of vitamin D3 and calcium during two 6-month pe-
riods and to assess their effect on the level of vitamin D.
Material and methods
Study design
This was a phase IV, two-armed, randomized, open,
cross-over study conducted in adult volunteers aged
50 years old or older. One hundred (100) volunteers
were randomized from a single investigational site in
Belgium in only 4 months (October 2012–February
2013). After the screening visit (month 0), volunteers
respecting all inclusion/exclusion criteria were divided
into two groups of treatment. One hundred volunteers
were randomized to receive either one drinkable am-
poule containing 25,000 IU vitamin D3 once monthly
(i.e. group VD) or one chewable tablet containing
1000 mg calcium carbonate+800 IU vitamin D3 once
daily (i.e. group VDCa) during 6 months. After the first
6 months of treatment, the groups were reversed and
each volunteer received the other treatment for another
period of 6 months according to the cross-over design.
Volunteers were asked to come to the investigator site
for three visits, during the study period: month 0, month
6 and month 12.
Subjects
Male and female subjects 50 years old or older with a body
mass index (BMI) between 18 and 35 kg/m2 were included in
this study. Volunteers who met any of the following criteria
were excluded from participating in the study: use of drugs
which may interfere with vitamin D metabolism (e.g. pheno-
barbital, phenytoin and oral and parenteral glucocorticoids),
use of any vitamin D supplement alone or in association (i.e.
multivitamin, vitamin D/calcium combination or vitamin
D/biphosphonate combination) within 4 weeks before the
screening visit; UV light solarium was used 2 weeks before
the screening visit and during the study.
All subjects provided written, informed consent to partici-
pate in the study, indicated by a personal signature and date on
the volunteer consent form.
Assessments
At screening (T0), demographics, medical history, previous
and concomitant medications, and vitamin D status were all
evaluated. Moreover, instructions for drug administration
were given. After 6 months, concomitant medications, ad-
verse events, compliance, persistence, treatment acceptability
and vitamin D status were also evaluated. At the end of the
study (T12), concomitant medications, compliance, persis-
tence, adverse events and treatment acceptability were again
evaluated. A questionnaire about the preferred treatment was
also submitted to the patients.
2864 Osteoporos Int (2015) 26:2863–2868
The following procedures were observed:
& Treatment compliance (i.e. the primary outcome): calcu-
lated as the number of tablets/ampoules taken by the pa-
tient divided by the number of tablets/ampoules to be tak-
en for a given period of time
& Vitamin D status: the level of 25(OH)D level was assessed
with the DiaSorin Liaison assay (Saluggia, Italy). In our
procedure, the CV was <8 %.
& Treatment preference: a questionnaire assessing the possi-
ble preference of the subject for one of the treatments was
given to all subjects. The reason, including taste, ease of
use, frequency of use, number of adverse events, reputa-
tion of the treatment, was also asked.
& Treatment acceptability: overall satisfaction was assessed
by a questionnaire. More specific questions on taste, ease
of use, frequency of use and occurrence of adverse events
were also asked.
& Adverse events (AEs): the number of events, but also the
number of patients, with emergent AEs, treatment-related
AEs, severe AEs, severe and treatment-related AEs, seri-
ous AEs (SAEs), treatment-related SAEs, withdrawals
due to AEs and withdrawals due to treatment-related
AEs were reported.
Statistical analysis
The Shapiro-Wilk test was utilized to test if population distri-
bution was normally distributed or not. Quantitative variables
were expressed by mean, standard deviation (SD) or median
and interquartile range (P25–P75) for asymmetric distribu-
tions. Qualitative variables were expressed by number and
percentage. For quantitative variables, comparison between
the two groups of treatment was assessed by means of a Stu-
dent t test for independent populations or a non-parametric
Mann-Whitney test if normality was not satisfied. The rela-
tionship between qualitative variables and group of treatment
was assessed using a chi2 test. As the study designwas a cross-
over study, compliance was analyzed according to the method
described in D. G. Altman (BStatistical methods for medical
research^, Chapman and Hall, London, 1991). This method
consists of testing a period/sequence effect, then an interaction
effect between period and treatment, and finally, and only in
case of no significant effect of period and interaction, a treat-
ment effect. All effects are assessed by using a two-sample t
test or a non-parametric test of Mann-Whitney. To test the
mean evolution of vitamin D between T0 and T6 within the
two treatment groups, a Student t test for independent samples
was used. The relationship between the main reasons of pref-
erence to a treatment and the chosen treatment was assessed
by a Fisher exact test. For each criterion of acceptability (taste,
ease of use, frequency of use, AEs and overall satisfaction),
the categories ‘not at all satisfied’, ‘slightly satisfied’ and
‘moderately satisfied’ were regrouped due to few data. For
the same reason, the categories ‘very much satisfied’ and ‘ex-
tremely satisfied’ were also regrouped. For each acceptability
criterion, the degree of satisfaction for the two treatments was
compared by means a McNemar test. Results were considered
to be statistically significant at the 5 % critical level (p<0.05).
Data analysis was carried out using SAS (version 9.3 for Win-
dows) and R (version 2.15) statistical packages.
Results
The first patient was randomized on October 15, 2012. A total
of 100 patients were enrolled over 4 months (last randomiza-
tion date February 14, 2013). The last visit took place on
February 17, 2014.
At baseline (T0), no significant differences were found in
any of the characteristics between the two groups of patients
(Table 1).
For the two periods, the compliance was higher in the VD
group than in the VDCa group (p<0.0001), and the greatest
difference in compliance rate was observed for patients who
changed from the VDCa group to the VD group. In both
periods 1 and 2, the compliance in the VD group was 100 %
(P25–P75 100–100) but was 96.2 % (83.1–100) and 91.7 %
(76.9–96.8) for the VDCa group, in periods 1 and 2,
respectively.
During the study, 50 (56.8 %) patients preferred the VD
treatment, 16 (18.2 %) patients preferred the VDCa treatment
and, for 22 (25.0 %) patients, neither treatment was preferred.
Interestingly, the treatments were chosen for different reasons
(p=0.030, Table 2). The main reason given by patients who
preferred the VD treatment was the frequency of use (42 %),
while VDCa was mainly chosen for its ease of use (62.4 %).
Proportions of patients who were ‘not at all satisfied’ to
‘moderately satisfied’ were different depending on the treat-
ment for the following acceptability criteria: (1) frequency of
Table 1 Baseline characteristics for the two groups of treatment
Variable Group 1 (n=50) Group 2 (n=49) p value
Age (years) 65.5 (57.4–72.7) 67.5 (61.2–73.8) 0.38
Median (P25–P75)
Weight (kg) 69.8±12.3 72.2±12.3 0.34
Mean±SD
Height (cm) 160.9±7.77 164.2±8.73 0.054
BMI (kg/m2) 26.9±4.10 26.7±3.76 0.82
25OHD (ng/mL) 29.7±11.2 27.6±10.1 0.34
Gender
Male 14 (28.0) 13 (26.5) 0.87
Female 36 (72.0) 36 (73.5)
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use (p=0.0023) and (2) adverse events (p=0.0010), patients
being less satisfied when taking VDCa treatment. No differ-
ence was found for taste and ease of use criteria. When ac-
ceptability criteria were considered as continuous variables,
satisfaction was higher with VD treatment for the following
acceptability criteria: (1) frequency of use (p=0.010), (2) ad-
verse events (p=0.0034) and (3) overall satisfaction
(p<0.0001) (Table 3).
During the first 6 months of follow-up, the mean (SD)
25(OH)D increased from 29.1 ng/mL (10.9) to 35.7 ng/mL
(8.85) in the VD group and from 27.9 ng/mL (10.2) to
31.8 ng/mL (8.8) in the VDCa group, without any statistical
differences between groups (p=0.16).
The incidence of adverse events related to treatment was
low but more frequently reported by subjects on VDCa
(Table 4).These adverse events related to treatment were gas-
trointestinal disorders (i.e. constipation, nausea and abdominal
upper pain).
Discussion
Strategies to improve patient compliance are of primary im-
portance. Many interventions, involving different factors, may
be considered. Indeed, there is evidence to support that a mul-
tifaceted strategy targeting cognitive, behavioural and
emotional factors is more effective than one aimed at a single
factor [26]. Preference of the patients also needs to be taken
into account [27]. Indeed, besides the potential effect on com-
pliance with treatment, the patient’s perspective is becoming
increasingly important in clinical and policy decisions. In our
study, more patients preferred D-Cure®, but the two treat-
ments (i.e. D-Cure® and Steovit Forte®) were chosen for dif-
ferent reasons. The frequency of use is the main reason given
for choosing vitamin D alone, but it should be pointed that the
potential reasons for preference were predefined.
Interestingly, increasing time between two doses has also
been suggested to improve compliance. However, and more
globally, the dose interval is still a matter of debate. On one
side, some studies have suggested that compliance with
monthly regimes could be better than with daily regimes [1].
On the other side, according to a recent review, it is likely that
for the optimal functioning of the endocrine/autocrine system,
significant 25OHD should be available on a daily basis to
ensure stable circulating concentrations, implying that varia-
tion in vitamin D dosing schedules could have profound ef-
fects on the outcomes of clinical trials because of the short
circulating half-life of intact vitamin D [24]. Consequently, the
balance between bioavailability and compliance needs to be
taken into account.
Anyway, it should be pointed out that although the exact
consequences of dose interval on bone health outcome are not
well known, the effect of the frequency of vitamin D admin-
istration on vitamin D status has already been investigated. In
our study, even if the monthly intake has improved the vitamin
D status more than the daily intake, it does not reach statistical
significance. Other studies have compared daily, weekly and
monthly vitamin D supplementation. In one 4-month study of
equivalent oral doses of vitamin D3 600 IU/day, 4200 IU/
week and 18,000 IU/month, daily dosing was the most and
monthly dosing the least effective to raise 25(OH)D concen-
trations [28]. In another 2-month study, intakes of 1500 IU of
D3 daily, 10,500 IUweekly and 45,000 IU once every 28 days
were equally effective [29]. In a 1-year study, intakes of
800 IU daily were more efficient than intakes of 97,333 IU
every 4 months to increase serum 25(OH)D3 concentrations
[30]. Another study, conducted over a period of 3 months,
showed no difference in the improvement of vitamin D status
Table 2 Association between chosen reasons of preference and chosen
treatment
VD group VDCa group Fisher exact
test
N (%) N (%) p
Reason Taste 2 (3.0) 3 (18.8) 0.030
Ease of use 17 (34.0) 10 (62.4)
Frequency of use 21 (42.0) 3 (18.8)
No adverse events 7 (14.0) 0 (0.0)
Treatment reputation 0 (0.0) 0 (0.0)
Other 3 (6.0) 0 (0.)
Total 50 (76.5) 16 (23.5)
Table 3 Association between
acceptability criteria considered
as continuous variables and
treatment
Acceptability VD group (n=87) VDCa group (n=87) Non-parametric p
Mean±SD M (P25–P75) Mean±SD M (P25–P75)
Taste 3.59±0.97 4 (3–4) 3.69±0.89 4 (3–4) 0.46
Ease of use 4.06±0.64 4 (4–4) 4.06±0.70 4 (4–4) 0.95
Frequency of use 4.06±0.57 4 (4–4) 3.77±0.83 4 (3–4) 0.010
Adverse events 4.24±0.63 4 (4–5) 3.90±1.06 4 (4–5) 0.0034
Overall satisfaction 2.91±0.29 3 (3–3) 2.63±0.65 3 (2–3) <0.0001
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between supplementations of 2000 IU/day or 60,000 IU/
month [31].
It should also be noted that even if most of the ep-
idemiological studies suggest that the prevalence of ad-
equate calcium intake is low, the supplementation of
calcium is not necessary in subjects with sufficient in-
take of calcium from food. Indeed, the best way to meet
the daily dietary calcium requirement is through the
intake of foods high in calcium: such as dairy products,
green vegetables, and mineral waters [10]. Dairy prod-
ucts may represent one of the best dietary sources of
calcium as they provide more calcium (and protein,
magnesium, potassium, zinc and phosphorus) per calorie
than any other typical food found in the adult diet [32].
The recommended consumption is three portions of
dairy products per day (for example, one glass of milk,
one portion of cheese and one yogurt). This amount
could provide most of the calcium needs of the general
population and could limit the use or the dose of calci-
um supplementation in the elderly. Another possibility
to improve calcium intake, keeping a once-monthly in-
take of vitamin D, would be with food fortification. A
variety of calcium-fortified foods, such as orange juice
and soy milk, are available in some countries and pro-
vide the same amount of calcium as dairy products.
Interestingly, it has been calculated, from the FINDIET
data, that calcium fortification of only 11 % of all
fortifiable foods would lead to a decrease of the propor-
tion of participants with calcium intake below the rec-
ommended level from 20.3 to 15.7 % in men and from
27.8 to 23.2 % in women [33].
We should acknowledge that besides the open-label design
of this study, a major limitation of this study is that no daily
calcium supplementation was given to the subjects from the
monthly dose of the vitamin D group. Obviously, the well-
known minor adverse events (e.g. gastrointestinal disorders)
observed with calcium supplementation could have affected
the compliance with the combined calcium/vitamin D product
that, in turn, could have influenced the vitamin D status.
However, because of the controversies regarding calcium sup-
plementation, some prescribers and some patients could be
willing to avoid such supplementation. In these circum-
stances, strategies to increase calcium intake through
calcium-fortified food should be activated.
On the other side, in Belgium, where this study was con-
ducted, there is no other supplement than D-Cure® containing
cholecalciferol alone. All specialities containing cholecalcif-
erol are combined with calcium. Steovit Forte® was chosen,
as the dose of cholecalciferol (800 IU/daily) is the closest to
that of D-Cure® (25.000 IU/month). It should then be pointed
out that the monthly total dose of vitamin D3 delivered in the
monthly supplement was 1000 IU greater than in the daily
supplement. The cost per month is 1.25€ for D-Cure® and
15.87€ for Steovit Forte®. In our study, a substantial propor-
tion of the volunteers were previously treated with D-Cure®
and/or Steovit Forte®. Therefore, both products were well
known by the volunteers before their entry in the study. In
addition, both products are available on the Belgium market
since many years and without prescription over the counter.
In conclusion, our study demonstrated that a monthly dose
of vitaminD is preferred to a daily combined administration of
calcium and vitamin D and leads to a better compliance but
without a significant difference in serum vitamin D concen-
tration between both regimes/treatments.
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Table 4 Summary table of
adverse events for the safety
population
VD group VDCa group FORTE
N (%) of patients N of events N (%) of patient N of events
Emergent AEs 54 (54.5) 102 58 (58.6) 107
Treatment-related AEs 4 (4.04) 10 10 (10.1) 11
Serious AEs 6 (6.06) 8 6 (6.06) 7
Treatment-related serious AEs 0 0 0 0
Withdrawals due to AEs 1(1.01) 1 3 (3.03) 3
Withdrawals due to
treatment-related AEs
0 0 2 (2.02) 2
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